UpdatesPress Release
Suven Life Sciences completed patient enrollment for its global Phase-3 Masupirdine study (SUVN-502) for Alzheimer’s Dementia agitation.
Suven Life Sciences LimitedSUVEN · Filed with the exchange
424 patients were randomized.
Topline results are anticipated by May 2027, signaling progress in its CNS pipeline.
No comments yet. Be the first.